Fortress Biotech Inc
Fortress Biotech Inc (FBIO) Covered Calls
Fortress Biotech Inc trades in the Biotechnology industry with an IV Rank of 53.17%, average versus the past year. FBIO's highest covered call setup is the $2.50 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 25.63% out of the money with 133 days to expiration, a 28.14% return until expiration, and a 77.23% theoretical annualized return. Across the setups shown, annualized returns run from 69.49% to 77.23% at strikes between $2.50 and $2.50, with 133 to 161 days to expiration, as of Nov 6, 2026.
Read more
Running FBIO covered calls helps you generate income from Fortress Biotech Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best FBIO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If FBIO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling FBIO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given FBIO covered call is worth writing.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.
| 2027-03-19 | 133 | 2.50 | 25.63 | 0.05 | 0.15 | 56.00 | 28.14 | 77.23 | -2.51 | +0.30 | 879 | 0.10 |
| 2027-04-16 | 161 | 2.50 | 25.63 | 0.10 | 0.35 | 61.00 | 30.65 | 69.49 | -5.03 | +0.42 | 1,198 | 0.25 |
As of Nov 6, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank53.17% Moderate
- Market cap (M$)63
- 52 weeks high-58.50%
- 52 weeks low5.03%
- Analyst recommendationStrong Buy
1.00 - Target price$5.00
165.96% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-13
- P/E0.71
- Future P/E—
- EPS (ttm)2.66
- EPS growth next 5 years—
As of Nov 13, 2026